ConductScience.org, home

Paper39006295

Clinical implications of serum miR-34a in breast cancer and its predictive value for the efficacy of neoadjuvant chemotherapy.

Hong Y and 4 others. Am J Transl Res, 2024. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Clinical implications of serum miR-34a in breast cancer and its predictive value for the efficacy of neoadjuvant chemotherapy. Papers, record 39006295. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39006295

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Clinical implications of serum miR-34a in breast cancer and its predictive value for the efficacy of neoadjuvant chemotherapy.
PubMed
Journal
Am J Transl Res
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
2
iCite
Relative citation ratio, by iCite
0.68, provisional
iCite
Revised in PubMed
2024-07-16
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Hong YYanyan
2Chen TTingting
3He QQian
4Ma QQiang
5Chen ZZhendong

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References25

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133971623MiR-205 suppressed the malignant behaviors of breast cancer cells by targeting CLDN11 via modulation of the epithelial-to-mesenchymal transition.Aging (Albany NY)2021https://conductscience.org/library/papers/33971623PubMed
234308576MiR-221 Expression Level Correlates with Insulin-Induced Doxorubicin Resistance in MCF-7 Breast Cancer Cells.Cell J2021https://conductscience.org/library/papers/34308576PubMed
332336285miR-615-3p promotes the epithelial-mesenchymal transition and metastasis of breast cancer by targeting PICK1/TGFBRI axis.J Exp Clin Cancer Res2020https://conductscience.org/library/papers/32336285PubMed
417888029Association of microRNA-34a overexpression with proliferation is cell type-dependent.Cancer Sci2007https://conductscience.org/library/papers/17888029PubMed
527062696Circulating microRNA-451 as a predictor of resistance to neoadjuvant chemotherapy in breast cancer.Cancer Biomark2016https://conductscience.org/library/papers/27062696PubMed
630860027Replication Study: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44.Elife2019https://conductscience.org/library/papers/30860027PubMed
734323695The synergy between miR-486-5p and tamoxifen causes profound cell death of tamoxifen-resistant breast cancer cells.Biomed Pharmacother2021https://conductscience.org/library/papers/34323695PubMed
836831192Potential miRNA Use as a Biomarker: From Breast Cancer Diagnosis to Metastasis.Cells2023https://conductscience.org/library/papers/36831192PubMed
934315439Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial.BMC Cancer2021https://conductscience.org/library/papers/34315439PubMed
1023001043MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1.Oncogene2013https://conductscience.org/library/papers/23001043PubMed
1129473328LncRNA HOTAIR influences cell growth, migration, invasion, and apoptosis via the miR-20a-5p/HMGA2 axis in breast cancer.Cancer Med2018https://conductscience.org/library/papers/29473328PubMed
1234281852Phase II Study of Nab-paclitaxel Plus Cyclophosphamide Plus Trastuzumab Neoadjuvant Chemotherapy in Early HER-2-positive Breast Cancer.Anticancer Res2021https://conductscience.org/library/papers/34281852PubMed
1331797701A Novel lncRNA HOXC-AS3 Acts as a miR-3922-5p Sponge to Promote Breast Cancer Metastasis.Cancer Invest2020https://conductscience.org/library/papers/31797701PubMed
1432144736miR-485-5p inhibits the progression of breast cancer cells by negatively regulating MUC1.Breast Cancer2020https://conductscience.org/library/papers/32144736PubMed
1532186770MicroRNA‑34a expression affects breast cancer invasion in vitro and patient survival via downregulation of E2F1 and E2F3 expression.Oncol Rep2020https://conductscience.org/library/papers/32186770PubMed
1625078559Neoadjuvant Chemotherapy in Breast Cancer Patients Induces miR-34a and miR-122 Expression.J Cell Physiol2015https://conductscience.org/library/papers/25078559PubMed
1732102529Dynamic Changes of Circulating Mir-155 Expression and the Potential Application as a Non-Invasive Biomarker in Breast Cancer.Asian Pac J Cancer Prev2020https://conductscience.org/library/papers/32102529PubMed
1834307126
Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study.
Front Oncol2021https://conductscience.org/library/papers/34307126PubMed
1934306209MicroRNA-301a-3p promotes triple-negative breast cancer progression through downregulating MEOX2.Exp Ther Med2021https://conductscience.org/library/papers/34306209PubMed
2035246810The Effect of Age on Outcomes After Neoadjuvant Chemotherapy for Breast Cancer.Ann Surg Oncol2022https://conductscience.org/library/papers/35246810PubMed

See all 25 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
42319671The role of circulating MiR-34a-5p and MiR-let7a-5p as a diagnostic tumor markers in breast cancer a cross-sectional analysis.Mol Biol Rep2026https://conductscience.org/library/papers/42319671PubMed
41749302Abnormal expression of miR-22-5p in breast cancer patients and its correlation with 18 F-FDG PET/CT features and serum-related tumor markers.World J Surg Oncol2026https://conductscience.org/library/papers/41749302PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
MIR34A407040PubTator's text mininghttps://conductscience.org/library/genes/407040

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39006295

GET https://conductscience.org/api/papers/v1/39006295/references?page=2